News
ALLO
1.040
-4.59%
-0.050
Allogene (ALLO) Q3 2026 Earnings Call Transcript
The Motley Fool · 1d ago
RBC Capital Sticks to Their Buy Rating for Allogene Therapeutics (ALLO)
TipRanks · 1d ago
Allogene Therapeutics Q3 2026 Earnings Call Transcript
Benzinga · 1d ago
Allogene Therapeutics Q3 EPS $(0.15), Inline
Benzinga · 1d ago
Here are the major earnings after the close Thursday
Seeking Alpha · 2d ago
Allogene's Autoimmune Data May Already Be Priced Into Expectations
Barchart · 3d ago
Weekly Report: what happened at ALLO last week (1026-1030)?
Weekly Report · 5d ago
Weekly Report: what happened at ALLO last week (1019-1023)?
Weekly Report · 10/26 09:41
Allogene Therapeutics participates in a conference call with JPMorgan
TipRanks · 10/21 16:45
Weekly Report: what happened at ALLO last week (1012-1016)?
Weekly Report · 10/19 09:41
Weekly Report: what happened at ALLO last week (1005-1009)?
Weekly Report · 10/12 09:44
Weekly Report: what happened at ALLO last week (0928-1002)?
Weekly Report · 10/05 09:43
We're Not Very Worried About Allogene Therapeutics' (NASDAQ:ALLO) Cash Burn Rate
Simply Wall St · 10/03 12:19
Buy Rating Reaffirmed on ALLO-329 Autoimmune Opportunity; Price Target Maintained at $14
TipRanks · 09/30 13:16
Weekly Report: what happened at ALLO last week (0921-0925)?
Weekly Report · 09/28 09:41
Weekly Report: what happened at ALLO last week (0914-0918)?
Weekly Report · 09/21 09:41
Cellectis Pivots to Gene Editing in Major Overhaul
Benzinga · 09/14 13:39
Weekly Report: what happened at ALLO last week (0907-0911)?
Weekly Report · 09/14 09:43
Stock Picks From Seeking Alpha's August 2026 New Analysts
Seeking Alpha · 09/08 14:00
Weekly Report: what happened at ALLO last week (0831-0904)?
Weekly Report · 09/07 09:40
More
Webull provides a variety of real-time ALLO stock news. You can receive the latest news about Allogene Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About ALLO
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.